FGL2 and neoplasm: To investigate the presence of Fgl2 in patients ith skin cutaneous melanoma (SKCM) more broadly, we queried the expression of Fgl2 in patients with primary melanoma versus melanoma metastasis through the tumor immune estimation resource (TIMER) database (48–50).